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Lessons from the field

Integration of comprehensive women’s health programmes into health
systems: cervical cancer prevention, care and control in Rwanda
Agnes Binagwaho,a Fidele Ngabo,a Claire M Wagner,b Cathy Mugeni,a Maurice Gatera,c Cameron T Nuttd &
Sabin Nsanzimanac
Problem Although it is highly preventable and treatable, cervical cancer is the most common and most deadly cancer among women in Rwanda.
Approach By mobilizing a diverse coalition of partnerships, Rwanda became the first country in Africa to develop and implement a national
strategic plan for cervical cancer prevention, screening and treatment.
Local setting Rwanda – a small, landlocked nation in East Africa with a population of 10.4 million – is well positioned to tackle a number
of “high-burden” noncommunicable diseases. The country’s integrated response to infectious diseases has resulted in steep declines in
premature mortality over the past decade.
Relevant changes In 2011–2012, Rwanda vaccinated 227 246 girls with all three doses of the human papillomavirus (HPV) vaccine. Among
eligible girls, three-dose coverage rates of 93.2% and 96.6% were achieved in 2011 and 2012, respectively. The country has also initiated
nationwide screening and treatment programmes that are based on visual inspection of the cervix with acetic acid, testing for HPV DNA,
cryotherapy, the loop electrosurgical excision procedure and various advanced treatment options.
Lessons learnt Low-income countries should begin to address cervical cancer by integrating prevention, screening and treatment into
routine women’s health services. This requires political will, cross-sectoral collaboration and planning, innovative partnerships and robust
monitoring and evaluation. With external support and adequate planning, high nationwide coverage rates for HPV vaccination and screening
for cervical cancer can be achieved within a few years.

Background
Cervical cancer is among the most common cancers affecting
women around the world.1 The estimated annual number of
deaths from cervical cancer – 275 000 – is similar to the annual
number of maternal deaths in childbirth.1,2 As is the case with
many other diseases, cervical cancer disproportionately affects
the poorest populations. Overall, 77% of new cases of cervical
cancer3 and 88% of deaths attributed to such cancer1 occur in
the developing world, where 95% of women have never been
screened for the disease.4
With adequate screening and early detection, the progression of precancerous cervical lesions can be completely
arrested in most cases, and cervical cancers in an early stage
are highly treatable. As a result, high-income countries with
good levels of screening have seen dramatic declines in the
incidence and mortality of cervical cancer in recent decades.5
Nearly all cases of cervical cancer are caused by the
human papillomavirus (HPV).6 Two prophylactic HPV vaccines can each prevent up to 70% of cervical cancer cases
and perhaps also some cancers of the vulva, vagina, anus,
penis and oropharynx that are related to HPV.6 These vaccines are being rolled out in a growing number of countries
on six continents and, with high coverage, could cause
massive reductions in the incidence of cervical cancer in
coming decades.6
Rwanda – a small, landlocked nation in East Africa with
a population of 10.4 million – is the first country in Africa to
develop and implement a national strategic plan for cervical

cancer prevention, care and control. Rwanda is well positioned to tackle some “high-burden” cancers, as its integrated
response to infectious diseases has resulted in steep declines
in premature mortality over the past decade.7 In the present
paper, we describe Rwanda’s strategic plan for cervical cancer
and its integration into the national health system; report the
plan’s progress to date; and offer recommendations to other
countries at similar decision points in the formulation of national health policies and the initiation of efforts to combat
cervical cancer.

Epidemiological imperative
Eastern Africa has one of the highest levels of mortality
among cases of cervical cancer in the world and women in
the region have a 2.7% cumulative probability of death from
cervical cancer.8 According to the age-standardized estimates
of the International Agency for Research on Cancer and the
World Health Organization, in 2008 Rwanda had 34.5 cases of
cervical cancer and 25.4 deaths attributable to cervical cancer
per 100 000 inhabitants.9 At the time, the incidence of cervical
cancer among Rwanda’s women appeared to be higher than
the combined incidences of breast, liver and stomach cancer.9
Female life expectancy at birth in Rwanda has climbed steadily
in recent years – to 61 years in 201110 – after stagnating between
29 and 35 years in the period surrounding the genocide in
1994.11 The annual incidence of cervical cancer would therefore
be expected to rise in the absence of nationwide interventions
against the disease.
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Despite sustained economic growth
since 2000, Rwanda remains one of
the poorest countries in the world and
does not have the financial flexibility to
build its own independent programme
against cervical cancer. Nearly half of
the country’s health budget is externally
financed. 12 The national government
recently had to decide what to do about
cervical cancer in the face of many other
competing health needs and financial
constraints.

Point of departure: HPV
vaccine
In 2009 – three years after an HPV
vaccine was introduced in the United
States of America – advocacy by Jeannette Kagame, the First Lady of Rwanda,
led to technical meetings between the
Rwandan Ministry of Health and Merck
& Co., the manufacturer of the quadrivalent HPV vaccine Gardasil. These
negotiations sparked a partnership for
the national rollout of the HPV vaccine
in Rwanda. Merck agreed to donate approximately 2 million doses of Gardasil
over a period of three years and to guarantee concessional pricing of the vaccine
to Rwanda and external funders thereafter. Simultaneously, the health ministry
initiated the planning phase for a comprehensive national programme for cervical cancer prevention, screening and
treatment. A demonstrated readiness to
integrate a vaccination for adolescents
into Rwanda’s national immunization
programme decreased the time required
to formulate strategy and initiate implementation. By 2010 – before rolling out
the HPV vaccine – Rwanda had already
achieved coverage rates exceeding 93%
of eligible subjects for vaccines against
nine diseases, including the pneumococcal conjugate vaccine.13 Following a
national consultation, Rwanda elected to
vaccinate all girls in grade 6 of primary
school, for free, on three designated
“health days” each year, beginning in
2011.14 These “health days” are now used
not only for HPV vaccination but also
for disseminating essential adolescent
health messages – to an otherwise hardto-reach age group – at regular intervals.
Beginning in 2012, these “health days”
have also been used for a nationwide
campaign of deworming for 3.8 million
children in primary schools. In 2012,
the deworming coincided with the first
HPV vaccine dose for the 2012 cohort.
In October 2012, delivery of the third
698

Table 1. Human papillomavirus vaccination coverage, Rwanda, 2011–2012
Coverage

2011
Round 1

No. of girls vaccinated
In schoola
91 752
Outside school
2 136
Overall
93 888
Cumulative coverage (%)b
95.0

2012

Round 2 Round 3

Round 1

Round 2 Round 3

89 704
3 066
92 770
93.9

137 147
1 162
138 309
98.8

134 645 134 115
845
1 024
135 490 135 139
96.8
96.6

88 927
3 180
92 107
93.2

The three rounds of vaccination in 2011 only covered girls who were in Grade 6 of primary school
whereas the rounds in 2012 covered girls who were then in Grade 6 of primary school or the third year of
secondary school.
b
The denominator for 2011: 98 792 eligible girls; denominator for 2012: 139 968 eligible girls.
a

vaccine dose for the 2012 cohort was
timed to overlap with another campaign: Rwanda’s annual Maternal and
Child Health Week. The latter campaign
involves sensitization about hand hygiene and reproductive health, delivery
of mebendazole, iron and folic acid to
pregnant women, and the provision of
vitamin A supplementation to children
and breastfeeding women.
By enlisting teachers and village
leaders in sensitization efforts and by
mobilizing the country’s 45 000 community health workers to trace out-ofschool girls, the HPV vaccination programme achieved a high coverage rate in
its first year: 92 107 (93.2%) of the 98 792
eligible girls identified in 2011 were fully
vaccinated (Table 1).14 Two “catch-up”
rounds of vaccination targeted girls
who were in the third year of secondary
school in 2012 or 2013. The aim was
to ensure that all girls younger than 15
years in 2011 had the opportunity to
receive a full course of HPV vaccination.
In 2012, the routine campaign targeting
girls in grade 6 of primary school led to
90 188 of the 93 243 eligible girls each
receiving three doses, while 394 of 549
out-of-school girls aged 12 years were
also fully vaccinated. The corresponding
“catch-up” campaign – targeting girls
in the third year of secondary school –
led to the full vaccination of 43 927 of
45 361 eligible in-school girls and 630
of 815 eligible out-of-school girls aged
14 years. In total, therefore, 135 139
(96.6%) of 139 968 eligible girls were
fully vaccinated in 2012 (Table 1).
There has been concern that some
countries that are eligible for support
from the Global Alliance for Vaccines
and Immunisation (GAVI) may lack
sufficient capacity to plan adequately,
manage cold chain deployment, navigate the nuances of communication,
achieve high coverage and mobilize

partners to ensure financial sustainability. 15,16 Rwanda’s experience and
success in scaling up access to HPV
vaccine indicates that these concerns
are largely unfounded. Halfway through
the first year of Rwanda’s HPV vaccination programme, Merck dropped the
price of the HPV vaccine by more than
70% from its previous lowest price per
dose – from 16.95 to 5.00 United States
dollars.17 Following GAVI’s incorporation of the HPV vaccine into its routine
funding portfolio in late 2012, further
price reductions have been announced,
with more expected in the near future.18
Merck’s partnership helped to bridge
the gap between Rwanda’s aspirations
for the prevention of cervical cancer
and the actions that the country was
able to implement against the disease.
Other private sector pharmaceutical
and medical device companies have
recently declared an interest in Rwanda’s
programme against cervical cancer. In
late 2011, for example, QIAGEN signed
a memorandum of understanding with
the Rwandan Ministry of Health and
agreed to donate equipment and consumables for HPV screening, beginning
in 2013.
Continued efforts to engage the
population in dialogue about the HPV
vaccine will be essential if high coverage
is to be sustained in Rwanda. As antivaccine activism has begun to find its
way – via the Internet and social media
– into communities across Africa, the
Rwandan Ministry of Health will maintain preparedness through campaigns of
mass sensitization and communication
with local leaders across the country.

Screening and diagnosis
In high-income countries, screening for
cervical cancer is generally integrated
into the annual consultations recom-
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Fig. 1. Cervical cancer screening and treatment in Rwanda, 2013
HIV-negative woman
aged 35–45 years,
recruited to health centre

CareHPV test performed
to detect high-risk forms
of HPV

–

Rescreen in 7 years
if HIV-negative and
3 years if HIV-positive

+
HIV-positive woman aged
30–50 years, recruited to
health centre

VIA test performed
on same day

–

Rescreen in 1 year

+
Small precancerous
lesions

Cryotherapy
on same day, at
health centre

Large precancerous
lesions
Lesions in the
endocervical canal

Suspected cancer

Refer to hospital
for LEEP

Refer for biopsy
and advanced
treatment

HIV, human immunodeficiency virus; HPV, human papillomavirus; LEEP, loop electrosurgical excision
procedure; VIA, visual inspection with acetic acid.
Note: It is expected that 10 to 15% of the women screened with the CareHPV test and 15 to 20% of those
screened by VIA will give a positive result (+). Of the women found to have abnormalities when visually
inspected, 75% are expected to have small precancerous lesions that can be covered by a cryoprobe;
20% are expected to have large precancerous lesions or lesions in the endocervical canal that cannot be
covered by a cryoprobe, and 5% are expected to have lesions suggestive of cervical cancer.

mended for women. However, in many
low- and middle-income countries most
women do not have access to such regular encounters with the primary-healthcare system. Fortunately, screening
methods for cervical cancer are diverse
and easily implemented. They include
testing for HPV DNA, the Papanicolaou
– or “pap smear”– test, visual inspection
with acetic acid, colposcopy and biopsy.
Precancerous lesions, or dysplasia, can
take 10 to 20 years to develop into cervical cancer. Therefore, even though early
detection is crucial, screening for cervical cancer can be effectively conducted
at longer intervals than screening for
breast cancer or other forms of cancer
that progress more rapidly than cervical
cancer.4 The costly and complex Papanicolaou tests appear to be of similar
sensitivity and specificity to the cheaper
and simpler visual inspection with acetic
acid, whereas colposcopy and biopsy
require specialization. In the detection
pathway developed by Rwanda and its
partners, testing for HPV DNA is therefore followed by visual inspection with
acetic acid and then, when necessary, by
colposcopy and biopsy (Fig. 1).
Before the implementation of the
national strategic plan for cervical

cancer prevention, care and control,
visual inspection of the cervix with
acetic acid was offered sporadically at
several public and private health facilities across Rwanda. With the equipment
and consumables donated by QIAGEN,
Rwanda will now scale up access to a
more diverse set of screening options
for cervical cancer that will initially be
offered in five district hospitals and 15
health centres in these hospitals’ catchment areas beginning in June 2013. If
everything goes to plan, cervical cancer
screening in Rwanda will be decentralized to 30 public hospitals and nearly
100 health centres by 2015. Between
2013 and 2016, QIAGEN will donate
250 000 assays and 29 machines for its
careHPV DNA testing system, while
the Rwandan government and other
partners will finance the scale-up of
visual inspection of the cervix with
acetic acid. As it is predicted that 18 700
of the donated careHPV assays will be
used incorrectly or for repeat tests, it has
been estimated that QIAGEN’s support
will allow 231 300 Rwandan women to
be tested for the DNA of the forms of
HPV associated with cervical cancer.
Since December 2012, nurses and
physicians performing the screening
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tests have been receiving intensive training. Eight national pathology trainers
will be trained by the American Society
for Clinical Pathology, and QIAGEN has
already trained eight laboratory technicians as trainers in reading the results of
tests for HPV DNA and histopathology.
Several of these 16 trainers will together
train another 32 pathologists and laboratory technicians by the end of 2013.
The National Reference Laboratory in
Kigali will receive technical support to
assume full responsibility for diagnosing
cervical cancer by 2015.
Starting in June 2013, at standard
meetings with nurses in Rwanda’s 15 000
villages, community health workers will
be told the dates when a mobile team
of one physician and two to four nurses
will visit the local health centre for HPV
screening over a three-day period. The
community health workers will enroll
women for free screening and then
return the corresponding enrolment
forms to the local health centre. The ages
of the women enrolled will depend on
whether they have been found infected
with human immunodeficiency virus
(HIV) – women known to be HIVpositive and aged 30 to 50 years will be
enrolled, as well as other women aged 35
to 45 years. Nurses will then report to
the district level, indicating the number
of women enrolled for each screening
day. These reports will allow the mobile
teams to determine the quantity of reagents needed and the likely duration
of the screening on each screening day.
With this system, it is expected that approximately 360 women will be tested in
a single day by each team. Each screened
woman will be asked to stay at the health
centre for a few hours, until the results of
her test are available. While waiting, she
will be educated about cervical cancer
and other aspects of reproductive health.

Treatment and palliative
care
The size, location and stage of a precancerous or cancerous lesion determine
the choice of treatment. The options
include cryotherapy, the loop electrosurgical excision procedure (LEEP), laser
surgery, hysterectomy, chemotherapy
and radiation therapy. For women who
receive cryotherapy or LEEP – two of the
most common methods for treatment
of early lesions in low-income settings
– cure rates, with the recommended
standard of care, approach 90%.19 Given
699
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Box 1. Summary of main lessons learnt
• It is feasible for low-income countries to integrate cervical cancer prevention, screening
and treatment into routine women’s health services.
• Such integration requires political will, cross-sectoral collaboration and planning, innovative
partnerships and robust monitoring and evaluation.
• With external support and adequate planning, high nationwide coverage rates for HPV
vaccination and screening for cervical cancer can be achieved within a few years.

this success rate – and the potential to
integrate screening for, and treatment
of, precancerous cervical lesions into
routine services for maternal and child
health, sexual and reproductive health,
and care for patients infected with HIV
infection – Rwanda chose to focus first
on cryotherapy and LEEP.
Cryotherapy involves using a cryoprobe emitting carbon dioxide or nitrous
oxide to freeze precancerous lesions on
the cervix. This procedure can generally
be performed within 15 minutes by a
trained physician, nurse or midwife at a
health centre. LEEP – which is primarily used for the removal of large lesions
that cannot be covered with a cryoprobe
or the removal of lesions involving the
endocervical canal – is performed by
physicians in hospital settings. In this
procedure, a thin, electrically heated
wire is used to remove lesions and any
transformed tissue, after the patient has
been given local anaesthesia.
Both cryotherapy and LEEP will be
scaled up for use in the same catchment
areas and on the same timeline as HPV
testing, and will be provided for free on
an outpatient basis. Cryotherapy will be
available at health centres and hospitals,
whereas LEEP will only be available in
hospitals. If a woman requires more
involved treatment for cervical cancer
– such as surgery, chemotherapy or
radiotherapy – she will be immediately
referred for biopsy and the necessary
advanced treatment. Although radiotherapy is not yet possible in the country,
Rwanda became a member of the International Atomic Energy Agency – an essential precursor to constructing an incountry radiation facility – in September
2012. As part of the Rwandan Human
Resources for Health Programme, the
Faculty of Medicine of the National University of Rwanda has begun a four-year
residency programme in pathology and
it is hoped that, in consequence, 12 new
pathologists will have graduated – and
many more will be in training – by 2018.
Little palliative care has been available in Rwanda because of the insuf700

ficient human resources available for
health care and the many competing
priorities for funding and advocacy.20
However, the national strategic plan for
cervical cancer prevention, care and
control is part of a larger movement in
Rwanda that aims to promote palliation.
As the country moves towards tackling
noncommunicable diseases – including
the drafting of a strategic plan for the
control of such diseases and the care
of patients with such diseases – it is
simultaneously strengthening comprehensive patient care, including palliative
and end-of-life care. Rwanda’s National
Palliative Care Policy was launched in
April 2011.21 By December 2012, 85%
of providers at the 42 district hospitals
in the country had been trained on
the national guidelines for palliation.
Morphine was added to the national
Essential Medicines List and is in the
process of being included in the supply chains of the 42 district hospitals
and the health centres in the hospitals’
catchment areas. The health ministry
is currently exploring the feasibility of
training up to 30 000 new community
health workers in the provision of palliative care at the community level for
patients with HIV infection, cancer and
other chronic conditions.

Programme costs and
sustainability
The launching of the first national programme for cervical cancer prevention,
care and control in Africa required a
commitment to plan for both long-term
sustainability and a high level of adaptability in a dynamic situation. Merck
and QIAGEN committed themselves
to donating to Rwanda and its funding partners HPV vaccines and DNA
testing machines and kits, respectively,
for three-year periods, and to offer
concessional pricing thereafter. These
donations have been complemented by
a range of investments by the Rwandan
government in additional equipment

and consumables, building supply chain
capacity, training and communication
campaigns.
In May 2013, GAVI announced that
it would support Rwanda’s national HPV
vaccination programme after Merck’s
donation ends in 2014.22 A coalition of
partners engaged in building Rwanda’s
cancer response, including the United
States Centers for Disease Control and
Prevention, will assist in scaling up
cervical cancer screening, treatment and
palliation.23 The Rwandan government
has committed itself to co-funding these
activities and expects that investments
in vaccination and early detection will
be offset by the prevention of invasive
cancers and premature deaths. 24 The
results of an in-depth costing analysis
of vaccination, screening and treatment
activities will be presented in a future
article.

Conclusion
Rwanda’s experience shows that – just
as international funding mechanisms
for HIV infection, tuberculosis and malaria have been harnessed to strengthen
primary care – a programme for the
control of cervical cancer can be used to
catalyse country investment in comprehensive systems of cancer care.25 A new
partnership with Susan G Komen for
the Cure that was launched in late 2012
will target the screening and treatment
of breast cancer in Rwanda. 9 In collaboration with development partners,
the Rwandan Ministry of Health opened
its first comprehensive cancer centre, at
Butaro District Hospital, in July 2012.
An additional ambulatory cancer care
centre was opened at the hospital in June
2013. Several of Rwanda’s referral hospitals have maintained cancer registries
over different periods since the 1990s; a
national cancer registry initiated in 2011
is now being scaled up to cover selected
district hospitals across the country.23
The key lessons learnt during the
early phases of Rwanda’s cervical cancer
programme (Box 1) include the value of
cross-sectoral collaboration and planning: of engaging development partners,
the national ministries of finance, gender,
youth and education, and local government; of conducting sustained campaigns
of communication and social mobilization that involve local leaders; of rigorously monitoring vaccination coverage
over time; and of systematically integrat-
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ing routine health services for women
into the primary-health-care system.
The world now has the tools to
prevent most cases of cervical cancer
and most deaths from the disease in the
coming decades, and these technologies
will certainly be brought to bear in resource-rich countries, where the burden
of cervical cancer continues to decline.6
However, if investments are not made in
delivering on public health’s potential
to address cervical cancer among the
poorest populations, inequalities in
outcome will grow even as the relevant
technology continues to improve. As a
pathology of poverty at the convergence
of infectious and noncommunicable
diseases, cervical cancer should feature

prominently in an integrated, post-2015
development agenda.26
Equitable access to the integrated
prevention, care and treatment of cervical cancer should be viewed as a triple
– epidemiological, economic and moral
– imperative.27 The cost of inaction is
massive and untenable. It has been estimated that every five-year delay in scaling up services for cervical cancer vaccination alone (not to mention screening
and treatment) in developing countries
will cost the lives of up to 2 million
additional women – many of them of
reproductive age and actively engaged
in the workforce.28 Ongoing efforts in
Rwanda and other countries to monitor
the incidence of cervical cancer and its

related mortality, the costs and impact
of HPV vaccination and screening, and
treatment outcomes, will help to inform
global efforts to promote evidence-based
action against cervical cancer. From
Rwanda’s perspective, the choice is clear:
it is time to stop debating whether to act
and to start fruitful exchanges on how
best to expand women’s access to preventive and curative services, optimize
service quality and ensure programme
sustainability. ■
Competing interests: None declared.

ملخص

 توقي رسطان عنق الرحم ورعايته ومكافحته يف رواندا:دمج برامج الصحة الشاملة للمرأة يف النظم الصحية

 وبدأت البلد كذلك يف برامج. عىل التوايل،2012 و2011 عامي
التحري والعالج عىل الصعيد الوطني التي استندت عىل الفحص
 وفحص احلمض،البرصي لعنق الرحم باستخدام محض اخلليك
، واملعاجلة بالتربيد،النووي لفريوس الورم احلليمي البرشي
وإج��راء االستئصال العروي باجلراحة الكهربائية وعدد من
.خيارات العالج املتقدمة
الدروس املستفادة ينبغي أن تبدأ البلدان املنخفضة الدخل التعامل
مع رسطان عنق الرحم عن طريق دمج التوقي والفحص والعالج
 ويتطلب ذلك إرادة سياسية.يف اخلدمات الصحية الروتينية للمرأة
وتعاون ًا وختطيط ًا بني مجيع القطاعات ورشاكات مبتكرة ورصد ًا
، ومن خالل الدعم اخلارجي والتخطيط املالئم.وتقيي ًام قويني
يمكن حتقيق معدالت تغطية مرتفعة عىل الصعيد الوطني يف تطعيم
فريوس الورم احلليمي البرشي وفحصه يف رسطان عنق الرحم يف
.غضون بضع سنوات

املشكلة عىل الرغم ارتفاع القدرة عىل توقي رسطان عنق الرحم
 إال أنه أكثر أنواع الرسطان شيوع ًا وأكثرها فتك ًا بني،وعالجه
.النساء يف رواندا
 أصبحت،األسلوب عن طريق حشد حتالف متنوع من الرشاكات
رواندا أول بلد يف أفريقيا يضع وينفذ خطة اسرتاتيجية وطنية لتوقي
.رسطان عنق الرحم وفحصه وعالجه
 دولة غري ساحلية صغرية يبلغ عدد سكاهنا- املواقع املحلية رواندا
 وهي يف وضع جيد يتيح-  مليون نسمة وتقع يف رشق أفريقيا10.4
.”هلا مواجهة عدد من األمراض غري السارية ذات “العبء الثقيل
ونتج عن املقاومة املتكاملة لألمراض املعدية يف البلد انخفاضات
.حادة يف معدل الوفيات املبكرة عىل مدار العقد املنرصم
 قامت رواندا،2012  إىل2011 التغيات ذات الصلة يف الفرتة من
ّر
 فتاة بكل الثالث جرعات من لقاح فريوس227246 بتطعيم
 وتم حتقيق معدالت التغطية للثالث.الورم احلليمي البرشي
 يف% 96.6 و% 93.2  بنسبة، بني الفتيات املؤهالت،جرعات

摘要
综合妇女健康计划与卫生系统整合 : 卢旺达宫颈癌的预防、护理和控制
问题 虽然宫颈癌高度可防可治 , 但是对于卢旺达妇女 93.2% 和 96.6% 的覆盖率。该国还发起全国性的筛查
却是最常见和最致命的癌症。
和治疗方案 , 该方案基于使用醋酸的子宫颈目视检查、
方法 通过动员多样化的伙伴关系联盟 , 卢旺达成为非 HPV DNA 测试、冷冻治疗、电圈切除术和各种先进
洲第一个制定和实施宫颈癌预防、筛查和治疗国家战 的治疗选项。
略计划的国家。
经验教训 低收入国家应该通过将预防、筛查和治疗与
当地状况 卢旺达 ( 一个人口 1040 万的东非内陆国家 ) 常规妇女保健服务整合来着手解决宫颈癌。这需要政
已作好准备来应对一批“高负担”非传染性疾病。在 治意愿、跨部门的协作和规划、创新的合作伙伴关系
过去十年 , 该国对传染性疾病的综合反应已经使得过 和强大的监测和评估。利用外部的支持和充分的规划 ,
早死亡率急剧下降。
可在几年内实现全国 HPV 疫苗和宫颈癌筛查高覆盖
2011
2012
227246
相关变化 在
–
年 , 卢旺达为
名女孩 率。
接种所有三剂人类乳头状瘤病毒 (HPV) 疫苗。在符合
条件的女孩中 , 分别在 2011 年和 2012 年实现三剂疫苗
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Résumé
Intégration de programmes de soins complets pour les femmes dans les systèmes de santé: prévention, traitement et lutte
contre le cancer du col de l’utérus au Rwanda
Problème Bien qu’il soit possible de le prévenir et de le guérir, le cancer
du col de l’utérus est le cancer le plus fréquent et le plus mortel chez
les femmes au Rwanda.
Approche En mobilisant une coalition hétéroclite de partenariats, le
Rwanda est devenu le premier pays d’Afrique à développer et à mettre
en œuvre un plan stratégique national pour la prévention, le dépistage
et le traitement du cancer du col de l’utérus.
Environnement local Le Rwanda, un petit pays enclavé d’Afrique
orientale, comptant 10,4 millions d’habitants, est bien positionné
pour s’attaquer à un certain nombre de maladies non transmissibles
constituant un «lourd fardeau». La réaction intégrée du pays aux
maladies infectieuses a entraîné une forte diminution de la mortalité
prématurée au cours de la dernière décennie.
Changements significatifs En 2011-2012, le Rwanda a vacciné
227 246 jeunes filles avec les trois doses du vaccin contre le virus du
papillome humain (VPH). Parmi les jeunes filles admissibles, les taux

d’administration des trois doses ont atteints 93,2% et 96,6% en 2011
et 2012, respectivement. Le pays a également lancé des programmes
nationaux de dépistage et de traitement, basés sur l’inspection visuelle
du col avec de l’acide acétique, le test de dépistage de l’ADN du VPH,
la cryothérapie, la technique d’excision électrochirurgicale à l’anse et
différentes options de traitement avancé.
Leçons tirées Les pays à faible revenu devraient commencer à lutter
contre le cancer du col de l’utérus en intégrant la prévention, le
dépistage et le traitement dans les services de soins de santé féminins
de routine. Cela exige une volonté politique, une collaboration et une
planification intersectorielle, des partenariats innovants, ainsi qu’un suivi
et une évaluation solides. Avec un soutien externe et une planification
adéquate, on peut atteindre en quelques années des taux nationaux
élevés de vaccination contre le VPH et de dépistage du cancer du col
de l’utérus.

Резюме
Интеграция комплексных программ по охране здоровья женщин в систему здравоохранения:
профилактика, оказание помощи и борьба с раком шейки матки в Руанде
Проблема Несмотря на наличие эффективных методов по
профилактике и лечению рака шейки матки, это заболевание
является одним из самых распространенных видов рака среди
женщин в Руанде, которое наиболее часто приводит к летальному
исходу.
Подход Проведя координацию деятельности союзов партнерских
организаций, Руанда стала первой африканской страной, которая
разработала и внедрила национальный стратегический план по
профилактике, выявлению и лечению рака шейки матки.
Местные условия Руанда — небольшая страна с населением 10,4
млн. человек в Восточной Африке, не имеющая выхода к морю.
Она занимает выгодное положение для проведения эффективной
борьбы с неинфекционными заболеваниями, имеющими тяжелые
последствия. Комплексный подход к проведению борьбы с
инфекционными заболеваниями в масштабах страны привел к
резкому снижению преждевременной смертности за последнее
десятилетие.
Осуществленные перемены На протяжении 2011–2012
годов в Руанде была проведена вакцинация 227 246 девочек
всеми тремя дозами вакцины против вируса папилломы

человека (ВПЧ). Среди отвечающих установленным критериям
девочек, все три дозы вакцины получили 93,2% и 96,6% из
них, в 2011 и 2012 годах соответственно. В стране были также
развернуты общенациональные программы по выявлению и
лечению этого заболевания, предусматривающие визуальное
обследование шейки матки с применением уксусной кислоты,
тестирование на наличие ДНК ВПЧ, криотерапию, процедуры
электрохирургического удаления петель и различные
прогрессивные методы лечения.
Выводы Страны с низким уровнем дохода должны приступить
к решению проблемы заболеваемости раком шейки матки. С
этой целью необходимо произвести интеграцию профилактики,
выявления и лечения в стандартную систему медицинского
обслуживания женщин. Для этого требуется политическая воля,
межотраслевое взаимодействие и планирование, применение
инноваций и тщательный контроль наряду с оценкой результатов.
При наличии внешней поддержки и адекватного планирования,
высокого уровня внедрения программы по вакцинации от ВПЧ
в масштабах страны и выявления рака шейки матки можно
достигнуть в течении нескольких лет.

Resumen
Incorporación de los programas integrales de salud femenina en los sistemas sanitarios: la prevención, la atención y el control
del cáncer de cuello uterino en Rwanda
Situación El cáncer cervical se puede prevenir y tratar en gran medida;
aun así, constituye el tipo de cáncer más común y mortal entre las
mujeres de Rwanda.
Enfoque Rwanda se convirtió en el primer país de África en desarrollar
e implementar un plan estratégico nacional para la prevención, la
detección y el tratamiento del cáncer cervical mediante la movilización
de una coalición heterogénea de asociaciones.
Marco regional Rwanda, un pequeño país sin litoral situado en el
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este de África con una población de 10,4 millones de habitantes,
está en condiciones de hacer frente a un conjunto de enfermedades
no transmisibles de «alta carga». La respuesta integral del país a las
enfermedades infecciosas ha permitido reducir en gran medida la
mortalidad prematura durante la última década.
Cambios importantes Entre 2011 y 2012, Rwanda vacunó a 227 246
niñas con las tres dosis de la vacuna contra el virus del papiloma humano
(VPH). Entre las chicas que cumplían con los requisitos, se alcanzaron
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tasas de cobertura de las tres dosis del 93,2 % y 96,6 % en 2011 y 2012,
respectivamente. Asimismo, el país ha puesto en marcha programas de
detección y tratamiento a nivel nacional, que se basan en la exploración
visual del cuello uterino con ácido acético, pruebas de ADN del VPH,
crioterapia, el procedimiento de escisión electroquirúrgica con asa y
otros tratamientos avanzados.
Lecciones aprendidas Los países con ingresos bajos deben comenzar
a tratar el cáncer cervical mediante la integración de la prevención,

la detección y el tratamiento en los servicios rutinarios de salud
femenina. Ello exige voluntad política, la planificación y la colaboración
intersectorial, el establecimiento de asociaciones innovadoras, así como
una evaluación y un seguimiento sólidos. Este objetivo podría alcanzarse
en pocos años mediante la ayuda externa y la planificación adecuada,
tasas elevadas de cobertura nacional de vacunación contra el VPH y la
detección del cáncer de cuello uterino.
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